Table 2.

Distribution of MLS resistance phenotypes by origin of the staphylococcal isolate (community-acquired versus hospital-acquired); p-value < 0.05 is considered as statistically significant.

	Staphylococcus spp., n (%)
	Community-acquired	Hospital-acquired	p-Value
Er/Cli S	546 (39.9)	97 (35.1)	0.16
cMLSb	128 (9.3)	19 (6.8)	0.20
M/MSb	218 (15.9)	71 (25.7)	0.0001
iMLSb	461 (33.7)	87 (31.5)	0.52
LSa/b	14 (1.0)	2 (0.7)	1.0
Total	1,367 (100.0)	276 (100.0)

Er/Cli S, susceptibility to erythromycin and clindamycin; cMLSb, constitutive resistance to macrolide–lincosamide–streptogramin B; M/MSb, resistance to macrolide/macrolide–streptogramin B; iMLSb, inducible resistance to macrolide–lincosamide–streptogramin B; LSa/b, resistance to lincosamide–streptogramin A/streptogramin B.